InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,604.40
(
-0.03%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.87
(
-0.73%
)
Bitcoin
62,899.78
(
-0.42%
)
Post# of 409
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ctcollins

Send PM Follow Ignore
Followers 8
Posts 406
Boards Moderated 0
Alias Born 03/14/2013

ctcollins

Re: None

Friday, 11/08/2019 7:32:32 AM

Friday, November 08, 2019 7:32:32 AM

Post# of 409
11:25 AM EST, 11/07/2019 (MT Newswires) -- Mallinckrodt (MNK), a maker of specialty pharmaceutical products, said Thursday that clinical results showed that multiple sclerosis relapse patients taking Acthar gel had a higher relapse resolution rate versus those taking intravenous or plasmapheresis treatment.
Acthar gel is currently approved by the US Food and Drug Administration for the treatment of acute exacerbations of multiple sclerosis in adult patients.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up